Paul G Fisher
Overview
Explore the profile of Paul G Fisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Upadhyaya S, Robinson G, Onar-Thomas A, Orr B, Johann P, Wu G, et al.
Clin Cancer Res
. 2021 Mar;
27(10):2879-2889.
PMID: 33737307
Purpose: Report relevance of molecular groups to clinicopathologic features, germline alterations (GLA), and survival of children with atypical teratoid rhabdoid tumor (ATRT) treated in two multi-institutional clinical trials. Materials And...
22.
Liu A, Wu G, Orr B, Lin T, Ashford J, Bass J, et al.
Neurooncol Adv
. 2021 Jan;
3(1):vdaa168.
PMID: 33506206
Background: Choroid plexus carcinoma (CPC) is a rare and aggressive tumor of infancy without a clear treatment strategy. This study describes the outcomes of children with CPC treated on the...
23.
Leach J, Roebker J, Schafer A, Baugh J, Chaney B, Fuller C, et al.
Neuro Oncol
. 2020 Jun;
22(11):1647-1657.
PMID: 32506137
Background: This study describes imaging features of diffuse intrinsic pontine glioma (DIPG) and correlates with overall survival (OS) and histone mutation status in the International DIPG Registry (IDIPGR). Methods: Four...
24.
25.
26.
27.
28.
29.
Jabarkheel R, Amayiri N, Yecies D, Huang Y, Toescu S, Nobre L, et al.
Neuro Oncol
. 2019 Sep;
22(2):290-297.
PMID: 31504816
Background: Cerebellar mutism syndrome (CMS) is a common complication following resection of posterior fossa tumors, most commonly after surgery for medulloblastoma. Medulloblastoma subgroups have historically been treated as a single...
30.
Reuter C, Kohler J, Bonner D, Zastrow D, Fernandez L, Dries A, et al.
J Genet Couns
. 2019 Sep;
28(6):1107-1118.
PMID: 31478310
Background: Despite growing evidence of diagnostic yield and clinical utility of whole exome sequencing (WES) in patients with undiagnosed diseases, there remain significant cost and reimbursement barriers limiting access to...